<p>Applications of daunorubicin-loaded PLGA-PLL-PEG-Tf nanoparticles in hematologic malignancies: an in vitro and in vivo evaluation</p>

Abstract

Background With the development of drug delivery, novel tools and technological approaches have captured the attention of researchers in recent years. Several target drug delivery systems (DDSs) including nanoparticles (NPs) have been developed as an important strategy to deliver classical medicine. Objective The objective of this study was to evaluate the application of novel daunorubicin (DNR)-loaded poly(lactic-co-glycolic acid)-poly- l -lysine-polyethylene glycol-transferrin (Tf) nanoparticles (DNR-loaded NPs) in hematologic malignancies in vitro and in vivo. Materials and methods DNR-loaded NPs were prepared by the modified double-emulsion solvent evaporation/diffusion method, and its microscopic form was observed under scanning electron microscope. Intracellular distribution of DNR was directly detected by fluorescence microscopy. After establishment of a tumor xenograft model by injecting K562 cells into the left leg of nude mice, the therapeutic effect of the DNR-loaded NPs on the growth of tumors was measured by calculating the tumor size, and the relative expression of Caspase-3 protein was detected by immunohistochemical staining. Furthermore, intracellular concentration of DNR and the extent of cell apoptosis in primary leukemia cells were quantified by flow cytometry. Results DNR-loaded NPs had a spherical shape of about 180 nm in diameter. DNR-loaded NP group showed a significant enhancement of cellular uptake in K562 cells compared with DNR group. Tumor inhibition rate was higher in DNR-loaded NP group in comparison with DNR group, and the relative expression of Caspase-3 protein was upregulated in DNR-loaded NP group compared with DNR group. Furthermore, DNR-loaded NPs obviously increased intracellular concentration of DNR in primary leukemia cells compared with DNR group, but there was no significant difference in primary cell apoptosis between the two groups. These findings suggest that the novel NP DDS can enhance the performance of conventional antitumor drugs and may be suitable for further application in the treatment of hematologic malignancies.

The clinical regimens and cell membrane camouflaged nanodrug delivery systems in hematologic malignancies treatment

“…Neha Mehrotra PhD et al constructed a polylactic acid (PLA)-based block copolymeric nanocarrier for the co-delivery of navitoclax and decitabine for AML therapy ( Mehrotra et al, 2023 ). Wen Bao et al used daunorubicin-loaded poly(lactic-co-glycolic acid)-poly-l-lysine-polyethylene glycol (PLGA-PLL-PEG)-transferrin nanoparticles achieved effective anti-leukemia treatment in vitro and in vivo ( Bao et al, 2019 ). Donato Cosco et al encapsulated miR-34a into chitosan/PLGA nanoparticles against multiple myeloma in vitro and in vivo ( Cosco et al, 2015 ).…”

Preclinical Assessment of Paclitaxel- and Trastuzumab-Delivering Magnetic Nanoparticles Fe3O4 for Treatment and Imaging of HER2-Positive Breast Cancer

“…Antitumor inhibition rate was defined as the inhibitory rate, calculated using the formula inhibitory rate (IR) (%): (1-average experimental group RTV/average control group RTV) × 100%. All studies were performed in adherence to the Guidelines for the Care and Use of Laboratory Animals established by the National Institute of Health (11).…”

“…The sections were incubated with anticleaved-Caspase 3 antibody (working dilution 1:100) at 4 • C overnight. After washing, the sections were reintubated with a secondary anti-mouse biotinylated antibody (1:1,000) in a dark room for 1 h. Positive cells were counted within five randomly selected horizons for each slice at a magnification of 400 × (8,11).…”

Iodine Nanoparticles (Niodx™) for Radiotherapy Enhancement of Glioblastoma and Other Cancers: An NCI Nanotechnology Characterization Laboratory Study

“…Rapidly dividing cells (e.g., tumor cells) require more iron and typically have upregulated TfR. Transferrin targeting has been shown to be effective in many tumor targeting studies using nanoparticles [ 29 , 31 , 32 , 33 , 34 , 35 ]. Preliminary tests of Niodx conjugated to Tf indicated 3–5 times greater U87 tumor cell binding and uptake of Niodx in vitro ( Figure 14 ).…”